Caduet's Japanese price may set precedent for combinations
This article was originally published in Scrip
Pfizer's combination cardiovascular product Caduet, Novartis's novel antihypertensive Rasilez and other products have been awarded prices in Japan and will be added to the reimbursement tariff on September 4th, clearing the way for launch.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.